Technology Bundle ID: TAB-2133

Novel Antigen for Use as Vaccine Against Nematode Infection

Request More Info
Licensing Contact:
Primary Inventors: 
Thomas Nutman (NIAID)
Co-Inventors: 
David Abraham (Thomas Jefferson University)
Therapeutic Area: 
Infectious Disease
Development Status: 

Early stage

Institute or Center: 
NIAID

This invention describes a new vaccine against Strongyoides stercoralis, which establishes a parasitic infection that affects an estimated 100-200 million people worldwide. The potential for fatal disease associated with S. stercoralis infection and the difficulty in treating hyperinfection underscores the need for prophylactic vaccines against the disease. This vaccine uses S. stercoralis immunoreactive antigen (SsIR); a novel antigen capable of providing 70-90 % protection for mice immunized with the antigen. In addition, sera from immunized mice have also been used to effectively protect naive mice from infection.

The invention may also have potential use in diminishing allergic responses, as Strongyoides stercoralis infection has been shown to reduce the murine response to allergens. Consequently, SsIR may be used to immunize individuals and reduce the allergic response. The antigen may also be used to identify homologous antigens from other parasitic nematodes that may be important for vaccine development.

Applications:
  • Vaccines against S. stercoralis infection
  • Discovery and use of other anti-parasitic antigens for vaccines
  • Potential for allergy therapy

Patents

PCT Application PCT/US2011/023320
Filed on 2011-02-01
US Application 61/301,426
Filed on 2010-02-04
US Pat 9,056,068

Issued 2015-06-16

License Status

Available for licensing

Updated

Jul 12, 2010

Data Source: 
tts